PHREESIA INC (PHR) Stock Fundamental Analysis
USA - NYSE:PHR - US71944F1066 - Common Stock
22.02 USD
-0.25 (-1.12%)
22.02 USD
0 (0%)
Overall PHR gets a fundamental rating of 4 out of 10. We evaluated PHR against 35 industry peers in the Health Care Technology industry. The financial health of PHR is average, but there are quite some concerns on its profitability. While showing a medium growth rate, PHR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year PHR has reported negative net income.
In the past year PHR had a positive cash flow from operations.
In the past 5 years PHR always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: PHR reported negative operating cash flow in multiple years.
1.2 Ratios
PHR has a better Return On Assets (-5.89%) than 68.57% of its industry peers.
PHR's Return On Equity of -8.07% is fine compared to the rest of the industry. PHR outperforms 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.89% | ||
| ROE | -8.07% | ||
| ROIC | N/A |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 68.02%, PHR is in the better half of the industry, outperforming 65.71% of the companies in the same industry.
In the last couple of years the Gross Margin of PHR has remained more or less at the same level.
PHR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
2. Health
2.1 Basic Checks
PHR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHR has more shares outstanding
Compared to 5 years ago, PHR has more shares outstanding
Compared to 1 year ago, PHR has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.71 indicates that PHR is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.71, PHR belongs to the best of the industry, outperforming 82.86% of the companies in the same industry.
PHR has a debt to FCF ratio of 0.42. This is a very positive value and a sign of high solvency as it would only need 0.42 years to pay back of all of its debts.
PHR's Debt to FCF ratio of 0.42 is fine compared to the rest of the industry. PHR outperforms 80.00% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that PHR is not too dependend on debt financing.
The Debt to Equity ratio of PHR (0.02) is better than 62.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.42 | ||
| Altman-Z | 5.71 |
ROIC/WACCN/A
WACC9.99%
2.3 Liquidity
A Current Ratio of 2.12 indicates that PHR has no problem at all paying its short term obligations.
PHR's Current ratio of 2.12 is in line compared to the rest of the industry. PHR outperforms 45.71% of its industry peers.
PHR has a Quick Ratio of 2.12. This indicates that PHR is financially healthy and has no problem in meeting its short term obligations.
PHR's Quick ratio of 2.12 is in line compared to the rest of the industry. PHR outperforms 45.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 2.12 |
3. Growth
3.1 Past
PHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.50%, which is quite impressive.
The Revenue has grown by 15.31% in the past year. This is quite good.
The Revenue has been growing by 27.46% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.23%
Revenue 1Y (TTM)15.31%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.83%
3.2 Future
PHR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.97% yearly.
Based on estimates for the next years, PHR will show a quite strong growth in Revenue. The Revenue will grow by 11.66% on average per year.
EPS Next Y96.48%
EPS Next 2Y52.47%
EPS Next 3Y40.97%
EPS Next 5YN/A
Revenue Next Year14.05%
Revenue Next 2Y13.08%
Revenue Next 3Y12.84%
Revenue Next 5Y11.66%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHR. In the last year negative earnings were reported.
PHR is valuated quite expensively with a Price/Forward Earnings ratio of 66.49.
The rest of the industry has a similar Price/Forward Earnings ratio as PHR.
The average S&P500 Price/Forward Earnings ratio is at 32.68. PHR is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 66.49 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHR is on the same level as its industry peers.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHR is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.3 | ||
| EV/EBITDA | 640.45 |
4.3 Compensation for Growth
PHR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PHR's earnings are expected to grow with 40.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.47%
EPS Next 3Y40.97%
5. Dividend
5.1 Amount
No dividends for PHR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22.02
-0.25 (-1.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners99.81%
Inst Owner Change1.07%
Ins Owners4.56%
Ins Owner Change-1.62%
Market Cap1.32B
Revenue(TTM)449.67M
Net Income(TTM)-24.05M
Analysts85
Price Target34.61 (57.18%)
Short Float %6.56%
Short Ratio4.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)78.63%
Min EPS beat(2)41.66%
Max EPS beat(2)115.6%
EPS beat(4)4
Avg EPS beat(4)51.25%
Min EPS beat(4)8.94%
Max EPS beat(4)115.6%
EPS beat(8)8
Avg EPS beat(8)37.38%
EPS beat(12)12
Avg EPS beat(12)31.19%
EPS beat(16)15
Avg EPS beat(16)26.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.27%
Min Revenue beat(2)-0.37%
Max Revenue beat(2)-0.18%
Revenue beat(4)0
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-0.56%
Max Revenue beat(4)-0.18%
Revenue beat(8)2
Avg Revenue beat(8)-0.13%
Revenue beat(12)5
Avg Revenue beat(12)0.4%
Revenue beat(16)9
Avg Revenue beat(16)1.43%
PT rev (1m)-0.63%
PT rev (3m)5.52%
EPS NQ rev (1m)-60%
EPS NQ rev (3m)91.34%
EPS NY rev (1m)29.04%
EPS NY rev (3m)75.68%
Revenue NQ rev (1m)-1.02%
Revenue NQ rev (3m)-0.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 66.49 | ||
| P/S | 2.93 | ||
| P/FCF | 47.3 | ||
| P/OCF | 25.5 | ||
| P/B | 4.43 | ||
| P/tB | 9.3 | ||
| EV/EBITDA | 640.45 |
EPS(TTM)-0.42
EYN/A
EPS(NY)0.33
Fwd EY1.5%
FCF(TTM)0.47
FCFY2.11%
OCF(TTM)0.86
OCFY3.92%
SpS7.51
BVpS4.97
TBVpS2.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.89% | ||
| ROE | -8.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% | ||
| FCFM | 6.2% |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
F-Score7
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.42 | ||
| Debt/EBITDA | 2.35 | ||
| Cap/Depr | 84.53% | ||
| Cap/Sales | 5.3% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 2655.34% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 2.12 | ||
| Altman-Z | 5.71 |
F-Score7
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)91.68%
Cap/Depr(5y)107.3%
Cap/Sales(3y)7.37%
Cap/Sales(5y)9.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.23%
EPS Next Y96.48%
EPS Next 2Y52.47%
EPS Next 3Y40.97%
EPS Next 5YN/A
Revenue 1Y (TTM)15.31%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.83%
Revenue Next Year14.05%
Revenue Next 2Y13.08%
Revenue Next 3Y12.84%
Revenue Next 5Y11.66%
EBIT growth 1Y73.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year249.5%
EBIT Next 3Y64.62%
EBIT Next 5Y37.25%
FCF growth 1Y132.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y186.75%
OCF growth 3YN/A
OCF growth 5Y108.09%
PHREESIA INC / PHR FAQ
Can you provide the ChartMill fundamental rating for PHREESIA INC?
ChartMill assigns a fundamental rating of 4 / 10 to PHR.
What is the valuation status for PHR stock?
ChartMill assigns a valuation rating of 3 / 10 to PHREESIA INC (PHR). This can be considered as Overvalued.
Can you provide the profitability details for PHREESIA INC?
PHREESIA INC (PHR) has a profitability rating of 2 / 10.
Is the dividend of PHREESIA INC sustainable?
The dividend rating of PHREESIA INC (PHR) is 0 / 10 and the dividend payout ratio is 0%.